ArticleFrontiers in oncology2025
Pregnancy after breast cancer treatment in young patients.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Breast cancer (BC) treatments can impair fertility in young women, causing considerable distress and potentially influencing treatment decisions, yet comprehensive real-world data on pregnancy outcomes after BC remain limited. This study aims to provide comprehensive real-world data on pregnancy following BC treatment to guide clinical practice and patient counseling. Methods: We conducted a retrospective cohort study using medical records from a single tertiary medical center in South Korea. The study included 995 premenopausal women aged 18 to 40 years who were diagnosed with stage 0-III BC between December 2010 and September 2020. The primary outcomes included post-treatment pregnancy rates, factors associated with subsequent pregnancy, timing of conception, pregnancy outcomes, and oncologic outcomes among those who conceived. Results: The median age was 32 years (interquartile range [IQR], 30-34 years). Of 995 patients, 115 had at least one pregnancy after their BC diagnosis. Significant differences in pregnancy rates and the interval from BC treatment to pregnancy were observed according to hormone receptor status and pregnancy history prior to BC diagnosis. Among those who conceived, 46.1% discontinued endocrine therapy (ET) to achieve pregnancy. Following BC treatment, pregnancies were observed in 7.8% of women who were >35 years old at diagnosis, 17.8% of women who were unmarried at diagnosis, and 6.8% of women who already had children. Of the 76 patients who discontinued ET to attempt pregnancy, 53 (69.7%) successfully conceived. Among those who achieved pregnancy after ET discontinuation, four patients (7.5%) experienced cancer recurrence. Discussion: Effective fertility preservation counseling is necessary for patients of reproductive age with BC, regardless of age, marital status, or whether they had children before BC diagnosis. This study can be referenced to appropriately address and manage the impact of chemotherapy and ET on pregnancy after BC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.